Compounds > azacitidine

azacitidine and Cancer, Second Primary

azacitidine has been researched along with Cancer, Second Primary in 29 studies

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (3.45)29.6817
2010's24 (82.76)24.3611
2020's4 (13.79)2.80

Authors

AuthorsStudies
Bauer, K; Berger, D; Bettelheim, P; Gamperl, S; Greiner, G; Hoermann, G; Knöbl, P; Kornauth, C; Schiefer, AI; Schwarzinger, I; Sillaber, C; Smiljkovic, D; Sperr, WR; Staber, PB; Stefanzl, G; Thalhammer, R; Valent, P1
Chu, HT; Fung, SH; Gill, H; Kwong, YL; Lee, E; Lee, P; Li, J; Liao, JJ; Miu, KK; Tse, E; Wang, Z; Yim, R; Yip, PK; Yung, Y1
Kolb, G; Reese, J; Velazquez, GF; Weckenbrock, J1
Angelopoulou, MK; Chatzidimitriou, C; Konstantopoulos, K; Korkolopoulou, P; Lafioniatis, S; Lakiotaki, E; Pappa, V; Plata, E; Vassilakopoulos, TP1
Bhalla, K; Boddu, PC; Cortes, JE; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Jain, N; Kadia, TM; Kantarjian, HM; Konopleva, M; Ohanian, M; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Verstovsek, S; Wierda, WG1
Eslin, D; Glade Bender, JL; Glasser, CL; Lee, A; Marks, L; Modak, S1
Hiraga, J; Kagami, Y; Kato, H; Narita, M; Suzuki, N; Takagi, Y; Ujihira, N1
Behrens, YL; Göhring, G; Lentes, J; Rothe, D; Schlegelberger, B; Steinemann, D; Thomay, K; Wittig, V; Wittner, N1
Imoto, S; Konuma, T; Miyano, S; Shimizu, E; Takahashi, S; Takei, T; Tojo, A; Yamaguchi, R; Yokoyama, K1
Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A1
Curtis, SA; Folkers, A; Medoff, E; Mixon, R; Shallis, RM; Xu, ML; Zeidan, AM1
Adès, L; Bally, C; Dartigeas, C; de Botton, S; de Renzis, B; Dreyfus, F; Fadlallah, J; Fenaux, P; Itzykson, R; Quesnel, B; Thépot, S; Turlure, P; Vey, N1
Ornstein, DL; Preis, M1
Hochhaus, A; Kunert, C; Schnetzke, U; Scholl, S; Schrenk, K; Spies-Weisshart, B1
Buquicchio, C; Galise, I; Greco, G; Guarini, A; Loseto, G; Melpignano, A; Merchionne, F; Minoia, C; Pavone, V; Sgherza, N; Tarantini, G; Toldo, C1
Jaksic, O; Kusec, R; Lasan-Trcic, R; Lucijanic, M; Pejsa, V; Stoos-Veic, T1
Garcia-Manero, G; Goswami, M; Hasserjian, RP; Jabbour, EJ; Medeiros, LJ; Patel, KP; Peng, J; Tang, G; Wang, SA1
Czader, M; Erba, HP; Figueroa, M; Gabrilove, J; Gore, SD; Greenberg, P; Herman, J; Juckett, M; Ketterling, RP; Litzow, M; Malick, L; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS; Zeidan, A1
Al-Kali, A; Baidoun, F; Elliott, M; Hashmi, S; Hogan, W; Hreh, M; Litzow, M; Patnaik, M; Subari, S1
Chua, N; Saini, L1
Annereau, M; Auger, N; Bermudez, E; Chahine, C; Danu, A; de Botton, S; Desmaris, RP; El Halabi, L; Ghez, D; Lazarovici, J; Leary, A; Lemare, F; Micol, JB; Pistilli, B; Saada, V; Solary, E; Willekens, C1
Carraway, H; Fandy, TE; Fernandez, H; Figueroa, ME; Gore, SD; Greally, JM; Jiemjit, A; Li, Y; Licht, JD; Melnick, A; Paietta, E; Skrabanek, L; Tallman, MS1
Guijarro-Llorca, J; Toledo-Alberola, F1
Devlin, SM; Dolezal, EK; Klimek, VM; Nimer, SD; Romero, A; Stein, K; Tees, MT1
Audureau, E; Bardet, V; Benet, B; Clozel, T; Dreyfus, F; Ettou, S; Fontenay, M; Humbrecht, C; Jammes, H; Lacombe, C; Mayeux, P; Solary, E1
Aloe Spiriti, A; Breccia, M; Criscuolo, M; D'Alò, F; Fianchi, L; Finelli, C; Gaidano, G; Hohaus, S; Leone, G; Leoni, P; Levis, A; Lunghi, M; Musto, P; Oliva, EN; Pagano, L; Santini, V; Voso, MT1
Bernal, T; Gutiérrez-Fernández, A; Moncada-Pazos, A; Soria-Valles, C1
Alimena, G; Breccia, M; Fianchi, L; Finelli, C; Gaidano, G; Hohaus, S; Leone, G; Leoni, P; Levis, A; Lunghi, M; Mansueto, G; Musto, P; Oliva, EN; Santini, V; Spiriti, MA; Voso, MT1
Al-Ali, NH; Alrawi, E; Duong, VH; Epling-Burnette, PK; Field, T; Komrokji, RS; Lancet, JE; List, AF; Perkins, J; Zhang, L1

Reviews

1 review(s) available for azacitidine and Cancer, Second Primary

ArticleYear
Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.
    Annals of hematology, 2018, Volume: 97, Issue:11

    Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; Azacitidine; Blood Transfusion; Breast Neoplasms; Female; Humans; Hydroxyurea; Isocitrate Dehydrogenase; Jehovah's Witnesses; Leukemia, Myeloid, Acute; Male; Myeloproliferative Disorders; Neoplasms, Second Primary; Treatment Refusal

2018

Trials

4 trial(s) available for azacitidine and Cancer, Second Primary

ArticleYear
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
    Leukemia research, 2013, Volume: 37, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Protocols; Azacitidine; Cohort Studies; Female; France; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Radiation Injuries; Societies, Medical; Young Adult

2013
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
    British journal of haematology, 2016, Volume: 172, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyridines; Treatment Outcome

2016
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
    Blood, 2009, Oct-15, Volume: 114, Issue:16

    Topics: Antigens, CD34; Azacitidine; Bone Marrow Cells; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Signaling System; Myelodysplastic Syndromes; Neoplasms, Second Primary; Promoter Regions, Genetic; Time Factors; Wnt Proteins

2009
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.
    Leukemia research, 2013, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Survival Rate; Time Factors

2013

Other Studies

24 other study(ies) available for azacitidine and Cancer, Second Primary

ArticleYear
Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis.
    Neoplasia (New York, N.Y.), 2021, Volume: 23, Issue:12

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Basophils; Female; Humans; Leukemia; Male; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms, Second Primary; Prognosis

2021
Epigenetic Silencing of
    International journal of molecular sciences, 2022, May-18, Volume: 23, Issue:10

    Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase

2022
[Treatment of secondary acute myeloid leukemia with azacitidine : Maintenance of quality of life and independence in advanced age].
    Zeitschrift fur Gerontologie und Geriatrie, 2020, Volume: 53, Issue:4

    Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Maintenance; Neoplasms, Second Primary; Quality of Life; Treatment Outcome

2020
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
    American journal of hematology, 2021, 05-01, Volume: 96, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blood Cell Count; Bone Marrow; Cancer Survivors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Diagnosis, Differential; Eosinophilia; Hemorrhagic Disorders; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine; Tryptases

2021
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Cancer, 2017, Aug-15, Volume: 123, Issue:16

    Topics: Aged; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms, Second Primary; Proportional Hazards Models; Remission Induction; Retrospective Studies; Treatment Outcome

2017
Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:7

    Topics: Adolescent; Antineoplastic Agents; Azacitidine; Decitabine; Drug Therapy, Combination; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Palliative Care; Quality of Life; Vorinostat

2017
EBV-positive Diffuse Large B-cell Lymphoma as a Secondary Malignancy Arising in a Myelodysplastic Syndrome Patient who Was Treated with Azacitidine.
    Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:13

    Topics: Azacitidine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary

2017
Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:10

    Topics: Aged; Aneuploidy; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 21; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; GTP Phosphohydrolases; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Membrane Proteins; Neoplasms, Second Primary

2018
Azacitidine effectively reduces
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cord Blood Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Prognosis; Salvage Therapy; Tumor Suppressor Protein p53

2018
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
    Annals of hematology, 2018, Volume: 97, Issue:11

    Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine

2018
The different faces of myelodysplasia in peripheral blood granulocytes.
    American journal of hematology, 2014, Volume: 89, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chemotherapy, Adjuvant; Decitabine; Female; Granulocytes; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Ovarian Neoplasms; Remission Induction

2014
Different clones of acute leukemia after successful treatment of Hodgkin's disease.
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Bleomycin; Bone Marrow; Clone Cells; Consolidation Chemotherapy; Dacarbazine; Doxorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Palliative Care; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vinblastine

2014
Azacitidine in the front-line treatment of therapy-related myeloid neoplasms: a multicenter case series.
    Anticancer research, 2015, Volume: 35, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retrospective Studies; Treatment Outcome

2015
Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia.
    Annals of hematology, 2015, Volume: 94, Issue:9

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Translocation, Genetic

2015
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biopsy; Bone Marrow; Chromosome Aberrations; Decitabine; DNA Methylation; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult

2016
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
    International journal of hematology, 2016, Volume: 103, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult

2016
Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:8

    Topics: Antibodies, Monoclonal; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Myositis; Neoplasms, Second Primary; Nivolumab; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2017
Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.
    Leukemia research, 2017, Volume: 55

    Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome

2017
Rapidly growing ulcer in a patient with neurofibromatosis type I.
    Actas dermo-sifiliograficas, 2012, Volume: 103, Issue:1

    Topics: Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Azacitidine; Fatal Outcome; Humans; Hypothyroidism; Immunocompromised Host; Leg Ulcer; Leukemia, Myelomonocytic, Chronic; Leukemic Infiltration; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Neoplasms, Second Primary; Neurofibromatosis 1; Pheochromocytoma; Pseudomonas Infections; Staphylococcal Infections

2012
Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.
    Leukemia research, 2012, Volume: 36, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retrospective Studies; Treatment Outcome

2012
Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
    Leukemia, 2012, Volume: 26, Issue:10

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; CpG Islands; DNA Methylation; fas Receptor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Promoter Regions, Genetic; Proportional Hazards Models; Risk

2012
Outcome of therapy-related myeloid neoplasms treated with azacitidine.
    Journal of hematology & oncology, 2012, Aug-01, Volume: 5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Remission Induction; Retrospective Studies; Survival Rate

2012
Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.
    Experimental hematology, 2013, Volume: 41, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Catalysis; Cell Line, Tumor; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Induction; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Second Primary; Promoter Regions, Genetic; Risk

2013
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:8

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Neoplasms, Second Primary; Treatment Outcome

2013